pharmaceuticals

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.

AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.